SEC Form SC 13G/A filed by Alector Inc. (Amendment)
$ALEC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2026 | Neutral → Overweight | Cantor Fitzgerald | |
| 3/10/2026 | $6.00 | Neutral → Buy | BTIG Research |
| 10/22/2025 | $1.50 | Outperform → Neutral | Mizuho |
| 10/22/2025 | Buy → Hold | TD Cowen | |
| 10/22/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 10/22/2025 | Outperform → Mkt Perform | William Blair | |
| 10/22/2025 | Buy → Neutral | BTIG Research | |
| 7/28/2025 | $3.50 | Neutral → Outperform | Mizuho |
SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
8-K - Alector, Inc. (0001653087) (Filer)
424B5 - Alector, Inc. (0001653087) (Filer)
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devasting progression of neurodegeneration, today report
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodege
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc.
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
Cantor Fitzgerald upgraded Alector from Neutral to Overweight
BTIG Research upgraded Alector from Neutral to Buy and set a new price target of $6.00
Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $1.50
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company
SC 13G - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)